UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Mar

    07

    BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

    Read More Share:linkedin| twitter| email| facebook

    Mar

    07

    BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Mar

    05

    Voices on Value: Prioritizing Patients Now and Into the Future

    Read More Share:linkedin| twitter| email| facebook

    Mar

    04

    CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

    Read More Share:linkedin| twitter| email| facebook

    Feb

    27

    On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

    Read More Share:linkedin| twitter| email| facebook

    Feb

    26

    Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

    Read More Share:linkedin| twitter| email| facebook

    Feb

    25

    Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

    Read More Share:linkedin| twitter| email| facebook

    Feb

    12

    Providing U.S. Policy Actions on Rare Disease

    Read More Share:linkedin| twitter| email| facebook

    Feb

    03

    Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

    Read More Share:linkedin| twitter| email| facebook

    Jan

    31

    Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2025 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: August 2025